Harmony Biosciences
HRMY
204 hedge funds and large institutions have $1.62B invested in Harmony Biosciences in 2023 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 86 increasing their positions, 56 reducing their positions, and 39 closing their positions.
119% more call options, than puts
Call options by funds: $9.47M | Put options by funds: $4.32M
54% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 56
3% less funds holding
Funds holding: 211 → 204 (-7)
4.31% less ownership
Funds ownership: 86.69% → 82.38% (-4.3%)
11% less capital invested
Capital invested by funds: $1.83B → $1.62B (-$205M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
18% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.64M |
| 3 |
PA
Perceptive Advisors
New York
|
+$3.64M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.07M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$19.4M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$15.2M |
| 3 |
Millennium Management
New York
|
-$13.3M |
| 4 |
Man Group
London,
United Kingdom
|
-$11.1M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$9.28M |
HRMY Hedge Fund Activity: Q3 2023 in Review
204 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q3 2023, worth a combined $1.62B — down 11% from $1.83B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of HRMY and 32 opened new positions — a net loss of 7 holders — while 56 trimmed existing stakes and 86 added.
The largest buyer was BlackRock, adding an estimated $13.3M. The largest seller was Citadel Advisors, cutting an estimated $19.4M.
- 204 institutional investors held Harmony Biosciences (HRMY) as of Q3 2023, down from 211 in Q2 2023.
- Funds reported $1.62B of Harmony Biosciences stock for Q3 2023, down 11% quarter-over-quarter.
- 32 funds opened new Harmony Biosciences positions in Q3 2023 and 39 closed out, a net change of -7 holders.
- The largest Harmony Biosciences buyer in Q3 2023 was BlackRock, an estimated $13.3M added.
- The largest Harmony Biosciences seller in Q3 2023 was Citadel Advisors, an estimated $19.4M sold.
Based on aggregated 13F filings for Q3 2023.